<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691441</url>
  </required_header>
  <id_info>
    <org_study_id>TopROC</org_study_id>
    <nct_id>NCT03691441</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer</brief_title>
  <official_title>Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Gießen and Marburg GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant
      Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial investigates the effectiveness of transoral head and neck surgery (TOS) for
      locally advanced, but transorally resectable oropharyngeal cancer followed by risk-adapted
      adjuvant therapy versus primary radiochemotherapy (definitive chemoradiotherapy, CRTX). Both
      treatments are internationally accepted standards. The choice of the treatment strategy
      depends on the preference of the responsible attending physician and on the country of
      residence. Internationally, mostly definitive chemoradiotherapy is regarded as the standard
      of care for oropharyngeal cancer. In Germany, however, transoral surgical resection is also
      well established and commonly practiced. The key question therefore is whether one of the two
      therapies is more effective than the other in clinical daily routine under the given
      conditions of our health care system and with a realistic, non-ideal patient cohort. For this
      reason, a comparative effectiveness research (CER) concept will be applied in this setting.
      The aim of this trial is primarily to show a superiority of the surgical approach in terms of
      local and locoregional control and secondarily to compare functional outcome and quality of
      life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2018</start_date>
  <completion_date type="Anticipated">June 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 5, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, two-arm, open label, multicenter, randomized, controlled comparative effectiveness study.
The trial is based on an event-driven design: the final analysis will be performed when all events have been observed or the study was terminated at one of the interim analyses.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to local or locoregional failure or death from any cause</measure>
    <time_frame>Defined as time from randomization up to 36 month</time_frame>
    <description>The primary objective of this study is to evaluate the effectiveness of primary surgical versus non-surgical treatment of patients with locally advanced, but transorally resectable oropharyngeal cancer in terms of time to local or locoregional failure or death from any cause (LRF).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Until 3 years after randomization</time_frame>
    <description>Overall survival (OS) in both study arms, follow-up visits until the end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Until 3 years after randomization</time_frame>
    <description>Disease-free survival (DFS) in both study arms. CT- Scans will be performed at month 3, month 6, 18, 30 and in case of suspicion of recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness in terms of toxicity</measure>
    <time_frame>Until 3 years after randomization</time_frame>
    <description>Effectiveness in terms of toxicity in both study arms. Monitoring of AE's/SAE's from randomization to 28 days after the last administration of IMP and/or 5 months after randomization in this trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effectiveness in terms of morbidity</measure>
    <time_frame>Until 3 years after randomization</time_frame>
    <description>Effectiveness in terms of morbidity (including swallowing function by MDADI Score) by late morbidity documentation in both study arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated by patient</measure>
    <time_frame>Until 3 years after randomization</time_frame>
    <description>Quality of life Questionnaires using QLQ H&amp;N-43 in both study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life evaluated by patient</measure>
    <time_frame>Until 3 years after randomization</time_frame>
    <description>CareQuality of life Questionnaires using EORTC QLQ-C30 both study arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-utility</measure>
    <time_frame>Until 3 years after randomization</time_frame>
    <description>Cost-utility in both study armsusing Questionnaire Health Care Utilization and Productivity loss.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost-effectiveness</measure>
    <time_frame>Until 3 years after randomization</time_frame>
    <description>Cost-effectiveness in both study arms using Questionnaire Health Utilization and Productivity loss.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Tertiary objectives include comparisons of treatment effects between HPV- Status</measure>
    <time_frame>Up to 36 month</time_frame>
    <description>Subgroup analysis of HPV-positive and HPV-negative oropharynx carcinoma</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>Resection/adjuvant radio(-chemo)therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transoral surgical resection within 4 weeks after randomization
Neck dissection can be performed during resection of the primary tumor or within 4 weeks after randomization
6-7 weeks standard risk-adapted adjuvant radio(-chemo)therapy 56-66 Gy (chemotherapy according to arm B if necessary), start within 6 weeks post-surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant radio(-chemo)therapy/salvage neck dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization
70-72 Gy, SIB possible
Cisplatin 100 mg/m2 on days 1, 22, 43 or Cisplatin once weekly (30-40 mg/m2) on days 1, 8, 15, 22, 29, 36 or Mitomycin C 10 mg/m2 d1, 29 and 5-FU 600 mg/m2/day iv on days 1-5 or Cisplatin 20 mg/m² + 5-FU 600 mg/m²/day iv d 1-5 and 29-33
+/- Salvage neck dissection 12±2 weeks after treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Resection</intervention_name>
    <description>Definitive surgery should generally be performed within 2 weeks, but not more than 4 weeks after randomization. The appropriately indicated neck dissection(s) may be performed either prior to, during the same session, or within 2 weeks after the resection of the primary tumor, but not later than 4 weeks following randomization. The primary tumor is to be resected with clear margins (R0) and en bloc in all cases. Frozen section assessment must be routinely and readily available.</description>
    <arm_group_label>Resection/adjuvant radio(-chemo)therapy</arm_group_label>
    <other_name>Transoral Surgery</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>6-7 weeks standard risk-adapted adjuvant radiotherapy 56-66 Gy, start within 6 weeks post-surgery Arm B: 6-7 weeks standard radiotherapy (IMRT-technique), start within 4 weeks after randomization, 70-72 Gy, SIB possible</description>
    <arm_group_label>Adjuvant radio(-chemo)therapy/salvage neck dissection</arm_group_label>
    <arm_group_label>Resection/adjuvant radio(-chemo)therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapy</intervention_name>
    <description>The investigational medicinal product (IMP) are the chemotherapeutical drugs Cisplatin, Mitomycin C and 5-FU. According to local routine, chemotherapy protocols as listed in study protocol should be used.</description>
    <arm_group_label>Adjuvant radio(-chemo)therapy/salvage neck dissection</arm_group_label>
    <arm_group_label>Resection/adjuvant radio(-chemo)therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Salvage neck dissection</intervention_name>
    <description>+/- Salvage neck dissection 12±2 weeks after treatment</description>
    <arm_group_label>Adjuvant radio(-chemo)therapy/salvage neck dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven SCC of the oropharynx; T1, N2a-c, M0; T2, N1-2c, M0; T3, N0-2c,
             M0, with only amendable to transoral resection)

          -  Primary tumor must be resectable through transoral approach

          -  p16 immunohistochemitry by local pathology or FFPE tissue must be available for
             central HPV diagnostic

          -  Written and signed informed consent

          -  Briefing through surgeon and radiation oncologist

          -  ECOG PS ≥2, Karnofsky PS ≥ 60 %

          -  Age ≥ 18

          -  Curative treatment intent

          -  Adequate bone marrow function: leucocytes &gt; 3.0 x 109/L, neutrophils &gt; 1.5 x 109/L,
             platelets &gt; 80 x 109/L, hemoglobin &gt; 9.5 g/dL

          -  Adequate liver function: Bilirubin &lt; 2.0 g/dL, SGOT, SGPT, &lt; 3 x ULN

          -  If of childbearing potential, willingness to use effective contraceptive method for
             the study duration and 2 months post-dosing.

          -  dental examination and appropriate dental therapy if needed prior to Confidential
             TopROC 2017_03_24 Version 1.0 Seite 15 von 124 beginning of radiotherapy

          -  Nutritional evaluation prior to initiation of therapy and optional prophylactic
             gastrostomy (PEG) tube placement

        Exclusion Criteria:

          -  Prior invasive malignancy except controlled skin cancer or carcinoma in situ of cervix

          -  Unknown primary (CUP), nasopharynx, hypopharynx, laryngeal or salivary gland cancer

          -  Metastatic disease

          -  Serious co-morbidity, e.g. high-grade carotid artery stenosis, congestive heart
             failure NYHA grade 3 and 4, liver cirrhosis CHILD C

          -  Hemoglobin level &lt;9.5g/dl within 4 weeks before randomization

          -  Pregnancy or lactation

          -  Women of child-bearing potential with unclear contraception

          -  Previous treatment with chemotherapy, radiotherapy, EGFR-targeting agents or surgery
             exceeding biopsy in head and neck

          -  Concurrent treatment with other experimental drugs or participation in another
             clinical trial with any investigational drug within 30 days prior to study screening

          -  Social situations that limit compliance with study requirements or patients with an
             unstable condition (e.g., psychiatric disorder, a recent history of drug or alcohol
             abuse, interfering with study compliance, within 6 months prior to screening) or
             otherwise thought to be unreliable or incapable of complying with the requirements of
             the protocol

          -  Patients institutionalized by official means or court order

          -  Deficient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chia-Jung Busch, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chia-Jung Busch, PD Dr.</last_name>
    <phone>0049(0)40741050038</phone>
    <email>cjbusch@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen Stromberger, PD Dr.</last_name>
    <phone>0049(0)30450527112</phone>
    <email>carmen.stromberger@charite.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitäts- HNO- Klinik Mannhein</name>
      <address>
        <city>Mannheim</city>
        <state>Baden- Würtemberg</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Lammert, PD Dr.med.</last_name>
      <phone>+49621383-3965</phone>
      <email>anne.lammert@umm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Vincentius- Kliniken Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Württemberg</state>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johannes Claßen, Prof. Dr.</last_name>
      <phone>+4972181085151</phone>
      <email>strahlenklinik@vincentius-ka.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Laban, Dr.</last_name>
      <phone>+4973150059501</phone>
      <email>simon.laban@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Amper- Klinikum Dachau</name>
      <address>
        <city>Dachau</city>
        <state>Bayern</state>
        <zip>85221</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Andratschke, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Jeanette Fendt</last_name>
      <phone>+49 (0)8131-76 6 88 88</phone>
      <email>Jeanette.Fendt@helios-gesundheit.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ruppiner Klinken GmbH</name>
      <address>
        <city>Neuruppin</city>
        <state>Brandenburg</state>
        <zip>16816</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Achim Franzen, Dr.</last_name>
      <phone>+49(0)3391/ 39 - 2014</phone>
      <email>a.schroeder@ruppiner-kliniken.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann gemeinnützige GmbH</name>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Maschmeyer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Rödel, Prof. Dr.</last_name>
      <email>claus.roedel@kgu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Wittenkindt, Prof. Dr.</last_name>
      <phone>+4964198543725</phone>
      <email>claus.wittekindt@hno.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg</name>
      <address>
        <city>Marburg</city>
        <state>Hessen</state>
        <zip>35037</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Boris A. Stuck, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elbekliniken Stade- Buxtehude GmbH, Klinikum Stade und Klinik Dr. Hancken</name>
      <address>
        <city>Stade</city>
        <state>Niedersachsen</state>
        <zip>21682</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Randolf Riemann, Prof. Dr.</last_name>
      <phone>+49 (0)4141 97-1301</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Wolfsburg</name>
      <address>
        <city>Wolfsburg</city>
        <state>Niedersachsen</state>
        <zip>38440</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Omid Majdani, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kreiskliniken Gummersbach-Waldbröl GmbH Klinik Oberberg</name>
      <address>
        <city>Gummersbach</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51643</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Holger Migdal</last_name>
      <phone>+49 (22 61) 17 - 11 67</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Grosheva, PD Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Stephanie Veith</last_name>
      <phone>+49 221 478-7808</phone>
      <email>stephanie.veith@uk-koeln.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Katholischen Krankenhaus Koblenz</name>
      <address>
        <city>Koblenz</city>
        <state>Rheinland-Pfalz</state>
        <zip>56073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harald Gorgulla, Dr. med.</last_name>
      <phone>+492614963979</phone>
      <email>H.Gorgulla@kk-km.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universität des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>22421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maximilian Linxweiler, Dr. med.</last_name>
      <phone>+4968411622900</phone>
      <email>maximilian.linxweiler@uks.eu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Leipzig / Borna Sana Kliniken Leipziger Land</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prof. Dr. Thomas Kuhnt</last_name>
      <phone>+ 49 (341) 97 18 210</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <state>Schleswig- Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Wollenberg, Prof. Dr.</last_name>
    </contact>
    <contact_backup>
      <last_name>Anna-Lena Spieler</last_name>
      <phone>+49 (0)451 500 75512</phone>
      <email>anna-lena.spieler@uksh.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <state>Thüringen</state>
        <zip>07757</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orlando Guintas- Lichius, Prof.Dr.</last_name>
      <phone>+4936419329301</phone>
      <email>Orlando.Guntinas@med.uni-jena.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Berlin Charité</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Stromberger, PD Dr.</last_name>
      <phone>+4930450527112</phone>
      <email>carmen.stromberger@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chia- Jung Busch, PD Dr.</last_name>
      <phone>004940741050038</phone>
      <email>cjbusch@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Krüll, PD Dr.</last_name>
      <phone>004940741055425</phone>
      <email>kruell@uke.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S. Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region. Head Neck. 2013 May;35(5):747-55. doi: 10.1002/hed.22015. Epub 2012 Jan 20. Review.</citation>
    <PMID>22267298</PMID>
  </reference>
  <reference>
    <citation>Licitra L, Zigon G, Gatta G, Sánchez MJ, Berrino F; EUROCARE Working Group. Human papillomavirus in HNSCC: a European epidemiologic perspective. Hematol Oncol Clin North Am. 2008 Dec;22(6):1143-53, vii-viii. doi: 10.1016/j.hoc.2008.10.002. Review.</citation>
    <PMID>19010264</PMID>
  </reference>
  <reference>
    <citation>Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008 Feb 1;26(4):612-9. doi: 10.1200/JCO.2007.14.1713.</citation>
    <PMID>18235120</PMID>
  </reference>
  <reference>
    <citation>Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, Kim H, Axelrod R, Silverman CC, Redmond KP, Gillison ML. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.</citation>
    <PMID>20530316</PMID>
  </reference>
  <reference>
    <citation>Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006 Feb 10;24(5):736-47. Epub 2006 Jan 9.</citation>
    <PMID>16401683</PMID>
  </reference>
  <reference>
    <citation>Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL Jr, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, Martins R, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Schuller DE, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian NR, Hughes M; National Comprehensive Cancer Network. Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2014 Oct;12(10):1454-87.</citation>
    <PMID>25313184</PMID>
  </reference>
  <reference>
    <citation>Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May;21 Suppl 5:v184-6. doi: 10.1093/annonc/mdq185.</citation>
    <PMID>20555077</PMID>
  </reference>
  <reference>
    <citation>Wegscheider K, Drabik A, Bleich C, Schulz H. [Benefit assessment in health services research and epidemiology]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2015 Mar;58(3):298-307. doi: 10.1007/s00103-014-2106-1. German.</citation>
    <PMID>25566839</PMID>
  </reference>
  <reference>
    <citation>Lörincz BB, Möckelmann N, Busch CJ, Knecht R. Functional outcomes, feasibility, and safety of resection of transoral robotic surgery: single-institution series of 35 consecutive cases of transoral robotic surgery for oropharyngeal squamous cell carcinoma. Head Neck. 2015 Nov;37(11):1618-24. doi: 10.1002/hed.23809. Epub 2014 Aug 28.</citation>
    <PMID>24955923</PMID>
  </reference>
  <reference>
    <citation>Boscolo-Rizzo P, Gava A, Baggio V, Marchiori C, Stellin M, Fuson R, Lamon S, Da Mosto MC. Matched survival analysis in patients with locoregionally advanced resectable oropharyngeal carcinoma: platinum-based induction and concurrent chemoradiotherapy versus primary surgical resection. Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):154-60. doi: 10.1016/j.ijrobp.2010.01.032. Epub 2010 Sep 23.</citation>
    <PMID>20864267</PMID>
  </reference>
  <reference>
    <citation>Hicks WL Jr, Kuriakose MA, Loree TR, Orner JB, Schwartz G, Mullins A, Donaldson C, Winston JM, Bakamjian VY. Surgery versus radiation therapy as single-modality treatment of tonsillar fossa carcinoma: the Roswell Park Cancer Institute experience (1971-1991). Laryngoscope. 1998 Jul;108(7):1014-9.</citation>
    <PMID>9665249</PMID>
  </reference>
  <reference>
    <citation>O'Hara J, MacKenzie K. Surgical versus non-surgical management of early stage oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2011 Mar;268(3):437-42. doi: 10.1007/s00405-010-1362-4. Epub 2010 Aug 27.</citation>
    <PMID>20799040</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2018</study_first_posted>
  <last_update_submitted>July 7, 2019</last_update_submitted>
  <last_update_submitted_qc>July 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>locally advanced</keyword>
  <keyword>transorally resectable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

